Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$26.86M+425.86%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Hutton
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 334
- Beta
- 0.59
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -5.21
Financials
Revenue
$26.86M+425.9%Net Income
$-7.27MEBITDA
$-4.10MFree Cash Flow
$-1.82MEPS (diluted)
$-0.71Shares Outstanding (diluted)
10.30M+688.0%Operating Expenses
$27.42MCash & Debt
$30.00MRevenue by Segment (annual)
$88.50MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $88.50M | $-35.27M | $-4.67 |
| 2024 | $71.32M | $-42.93M | $-6.62 |
| 2023 | $49.09M | $-52.15M | $-12.70 |
| 2022 | $38.21M | $-65.45M | $-31.09 |
| 2021 | $54.51M | $-43.16M | $-31.54 |
| 2020 | $45.56M | $-31.35M | $-23.61 |
| 2019 | $24.55M | $-30.73M | $-2410.66 |
| 2018 | $20.43M | $-26.17M | $-19.72 |
Valuation
BDSXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (8)
- Newszacks.com·7d ago·Neutral
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:
View source ↗ - Newszacks.com·35d ago·Positive
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·35d ago·Neutral
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High? The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
View source ↗ - Newszacks.com·55d ago·Positive
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-0.75 per share
Typical surprise +21.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.71 vs $-0.90beat
- Mon, May 4$-0.81 vs $-1.26beat
- Thu, Feb 26$-0.49 vs $-1.05beat
- Mon, Nov 3$-1.16 vs $-1.60beat
- Thu, Aug 7$-1.60 vs $-1.40miss
- Tue, May 13$-1.60 vs $-1.40miss
Estimates and results for BDSX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDSX officers and directors.
- Bought
- $4.1m
- Sold
- $118k
8 trades
20 trades
- Schuler Jack Wbought
- Schuler Jack Wbought
- Schuler Jack Wbought
- Pestano Gary Anthonysold
- O'kane Kieransold
- Cowie Robin Harpersold
- Vazquez Chrissold
- Hutton Scottsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BDSX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.